Fig. 4. Reduction of dfna5 activity leads to abnormal ear and cartilage development. (A-C) Lateral views of wild-type (A), 15 ng dfna5 ATG-MO-injected (B) and 25 ng dfna5 ATGMO-injected (C) embryos, indicating a dose-dependent malformation of the lower jaw (arrows). (D,E) Dorsal view of wild-type (D) and 20 ng dfna5 ATG-MO-injected (E) embryos at day 5, showing malformation of the anterior and posterior column in the morphant ear (arrows). (F,G) Close up of the right ear in D and E, respectively. (G) The anterior column (ac, arrow) of the morphant is malformed, the posterior column (pc, large arrows) is interrupted. (H-J) Lateral view of the ear at day 5 (anterior towards the left, ventral towards the bottom) of wild type (H), 15 ng dfna5 ATG-MO injected (I) and 25 ng dfna5 ATG-MO injected (J) embryos. In morphants, either one or more columns do not fuse (arrows), depending on the injected dose of dfna5 ATGMO. ao, anterior otolith; po, posterior otolith. Scale bar: 300 µm in A-C; 250 µm in D,E; 80 µm in F,G; 125 µm in HJ. ac, anterior column; pc, posterior column.